Sajjan India Limited is looking for expansion, both organically and through acquisitions, to achieve the planned growth
Columvi is part of Roche's industry-leading portfolio of T-cell engaging bispecific antibodies in non-Hodgkin lymphoma, which also includes the recently approved Lunsumio to treat follicular lymphoma
The increased drug load enabled by the nanoformed particles also allows smaller implants with sustained release properties to be developed.
Approximately 60 to 78% of individuals diagnosed with Asthma also have concurrent Allergic Rhinitis
Laurus will also provide funding for the clinical trials and will launch these products in India and emerging markets
Acquisition delivers industry-leading research capability, and strengthens pipeline with a novel candidate for ulcerative colitis, Crohn’s disease and other autoimmune conditions
Convergent action on AMR identified as an important area of intervention
Urges Innovators to produce quality products that can be deployed at scale
Investment enables development of revolutionary multi-omic platform using super-resolution imaging technology for earlier disease detection and accelerated discovery of therapeutics
The new range of HDPE bottles is compliant with US FDA, EU regulations and Chinese DMF registration for use in dry pharmaceutical applications
Subscribe To Our Newsletter & Stay Updated
